Adjuvant treatment of chronic osteomyelitis of the tibia following exogenous trauma using OSTEOSET\textsuperscript{R}-T: a review of 21 patients in a regional trauma centre

Gemma Humm · Saqib Noor · Philippa Bridgeman · Michael David · Deepa Bose

Received: 22 November 2013 / Accepted: 12 December 2014 / Published online: 25 December 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract  Surgical debridement and prolonged systemic antibiotic therapy are an established management strategy for infection after tibial fractures. Local antibiotic delivery via cement beads has shown improved outcome but requires further surgery for extraction of beads. OSTEOSET\textsuperscript{R}-T is a resorbable bone void filler composed of calcium sulphate and 4\% tobramycin that is packed easily into bone defects. This is a review of the outcomes of 21 patients treated with OSTEOSET\textsuperscript{R}-T for osteomyelitis of the tibia. This is a retrospective case note and clinical review. In all cases, the strategy was debridement, with removal of any implants, with excision back to bleeding bone. OSTEOSET\textsuperscript{R}-T pellets were packed into any contained defects or the intra-medullary canal with further bony stabilisation ($n=9$) and soft tissue reconstruction ($n=7$) undertaken as required. Intravenous vancomycin and meropenem were administered after sampling with substitution to targeted antibiotic therapy for between 6 weeks and 6 months. The average follow-up was 15 months. Union rate after tibial reconstruction was 100\%. Wound complications were encountered in 52\%: a wound discharge in the early post-operative period was noted in seven patients (33\%) independent of site of pellet placement. In the 14 cases without a wound leak, five developed wound complications ($p=0.06$, Fisher’s exact test) either from delayed wound-healing or pin-site infections. One patient developed a transient acute kidney injury and one refractory osteomyelitis. OSTEOSET\textsuperscript{R}-T is an effective adjunct in the treatment of chronic tibial osteomyelitis following trauma based on the low incidence of relapse of infection within the period of follow-up in this study, but significant wound complications and one transient nephrotoxic event were also recorded.

Keywords  Osteomyelitis · Tibia · Trauma · Osteoset · Antibiotic

Introduction

Antibiotics are an important part of the strategy in treating infection after tibial fractures. In established osteomyelitis, surgical debridement is followed with systemic and, sometimes, local antibiotic delivery. Antibiotic-impregnated cement beads are frequently used as an adjunct to delivery of antibiotics but often require a further surgical procedure for removal.

The ability to treat chronic osteomyelitis with single-stage surgery potentially reduces the risk and morbidity associated with repeated operative procedures and general anaesthetic. Reduction in theatre time and length of inpatient stay are added economic benefits. Despite single-stage surgery showing reasonable success in achieving union in infected non-union of long bones, persistent infection and subsequent revision surgery may be needed [1].

Calcium sulphate has been used successfully in the treatment of non-union and is an osteo-conductive void filler that is resorbed at a rate similar to that of bone formation [2, 3]. OSTEOSET\textsuperscript{R}-T (Wright Medical Technology Inc. Arlington TN USA) comes pre-packaged in small pellets to allow easy packing into bone. It comes preloaded
Staphylococcus and Enterobacteriaceae/C210 value of B are sensitive to tobramycin/C210

Cases of non-union and the presence of metal work in acute fractures were resolved after the complete absorption of OSTEOSET/C210. No further surgery was required to remove the resorbable pellets. Animal studies have demonstrated that its use prevents complications, e.g. in the development of sinuses draining a sterile effluent, but this was found to be self-limiting and resolved after the complete absorption of OSTEOSET/C210 and without recurrence of infection [9, 10].

The aminoglycosides used in the treatment of bone infections belong to the protein synthesis inhibitor family of antibiotics, binding to the bacterial ribosomal 30S subunit to achieve a bacteriostatic effect through transcription errors during cell division [11]. An additional ability to disrupt bacterial cell membranes accounts for its bactericidal properties [12]. They have a broad spectrum and are effective against both gram-positive and gram-negative organisms [13]. Pseudomonas aeruginosa, Staphylococcus aureus and Enterobacteriaceae are sensitive to tobramycin which has a lower side-effect profile than gentamicin [14].

This case series reports on the outcome of 21 patients with chronic osteomyelitis managed by single-stage surgery and using OSTEOSET®-T as an adjunct to intravenous antimicrobial therapy.

Materials and Methods

Twenty-one cases of chronic tibial osteomyelitis in which treatment involved the use of OSTEOSET®-T as a space filler and local antibiotic delivery system were identified by a retrospective review over a 30-month period from 2010 to 2012. Data were collected using a proforma and included demographics, record of the intra-operative procedure, relevant microbiology, renal function, complications relating to recurrent infection and wound healing, the presence of a wound leak and repeat surgeries. A wound leak was defined subjectively as a serous leakage considered a potential risk to normal wound healing [15]. A standardised surgical protocol and antibiotic regime based on guidance from our local microbiology department were followed.

In all cases, surgery was directed at excising infected tissue and sinuses; a radical debridement was performed, guided by pre-operative magnetic resonance imaging, until bleeding confirmed on residual bone. Metalwork, if present, was removed. Once complete, OSTEOSET®-T pellets were packed into any defects or into the intra-medullary canal in those cases where an intramedullary nail had been removed. Further, tibial stabilisation and soft tissue cover were carried out as deemed necessary. The protocol involved taking a minimum of five tissue samples from deep tissues using fresh instruments for each sample. Empiric intravenous vancomycin and meropenem were administered after samples were taken. Meropenem was discontinued after 3 days in the absence of gram-negative growth, and vancomycin continued until the 7-day culture results became available. Thereafter, targeted antibiotic therapy was continued for a period of 6 weeks to 6 months, or empiric ciprofloxacin and rifampicin if no growth was seen. This approach is based on the probability of involvement of a Staphylococcus bacterium species contraposed to local antibiotic resistance patterns and the previous published literature on the effectiveness of combination of dual therapy [15–17].

Data analysis and parametric tests were performed using Microsoft Excel for Mac 2011, while nonparametric statistical tests done with GraphPad QuickCalcs (2013 GraphPad Software, Inc.). Statistical significance was set at p value of ≤0.05.

Results

There were 18 males and 3 females with a mean age of 49 (range 26–88) and follow-up of 16 months (range 6–25). Six patients were classified as Cierney-Mader grade 3A, one patient as grade 3B, 13 patients grade 4A, and one patient grade 4B. In situ metal work was removed (Fig. 1).
Nine cases required fixation: eight with circular external fixators and one with a monolateral external fixator. Seven cases required reconstructive soft tissue cover provided by our resident plastic surgical team: there were four local flaps and three free vascularised flaps.

Microbiological analysis of the samples revealed 38% of the infections were caused by a strain of *Staphylococcus* species. A significant number either had mixed growth or no identified growth. This is summarised in Table 1. Renal function was assessed in all cases. One case was complicated by a transient post-operative acute kidney injury which resolved after 1 week without the need for renal support. This patient had pre-existing comorbidities of obesity and essential hypertension.

Seven cases were complicated by wound leakage; the location of OSTEOSET®-T pellets in either a closed intramedullary cavity or an open cortical defect did not relate to its incidence (Fig. 2). Three-quarters of these cases with a wound leak went on to have problems with wound healing as compared to just one-third of the cases without a leak. A serous leak appears to double the relative risk of wound-healing problems (Fig. 3).

Successful eradication of infection, as determined in the time of follow-up in this series, was achieved in 20 cases.

### Table 1 Causative organisms involved

| Organism                        | Cases | %  |
|---------------------------------|-------|----|
| Polymicrobial                   | 4     | 19 |
| Coagulase-negative *Staphylococi* | 4     | 19 |
| *Staphylococcus aureus*         | 4     | 19 |
| Negative cultures               | 3     | 14 |
| Other organisms                 | 6     | 29 |
| *Serratia* sp.                  | 2     |    |
| *Corynebacterium* sp.           | 1     |    |
| *Enterococcus* sp.              | 1     |    |
| Mixed anaerobes                 | 1     |    |
| *Propionibacterium*             | 1     |    |

Fig. 2 Impact of site of placement of OSTEOSET®-T placement and the presence of a post-operative wound leak ($p = 1.0$, Fisher’s exact test)

Fig. 3 Impact of wound leakage on healing ($p = 0.06$, Fisher’s exact test)

Fig. 4 Pre-operative plain radiograph of the right distal tibial in a 57 year old male with chronic post-traumatic osteomyelitis distal tibia

Only one patient required further debridement and soft tissue coverage and remained free of continuing infection at latest follow-up. One patient required further surgery for the correction of residual deformity.

Figures 4, 5, 6, 7 and 8 show the successful management of a 57 year old man with post traumatic chronic tibial osteomyelitis using OSTEOSET®-T as an adjunct to surgical debridement.

### Discussion

This case series included a sample of patients with chronic osteomyelitis of the tibia secondary to trauma. The use of OSTEOSET®-T was an effective adjunct with eradication of infection in all of our cases in the period of follow-up, although one patient required a further surgical debridement owing to an unhealthy appearance of the wound and suspected
persistent infection. The occurrence of a sterile effluent was a significant complication, as was its associated risk of impaired wound healing. Reported concerns over acute kidney injury (potential nephrotoxic side-effect of high local concentrations of aminoglycosides) were unfounded in our series; the one incident of transient acute kidney injury seen was thought to have occurred from the intravenous antimicrobial therapy in a patient with a background of hypertensive nephropathy.

This case series is limited by the following: the absence of a control group, small numbers and the minimum follow-up period of 6 months. A retrospective case–control study, which contained a mixed group of long-bone infections, found favour in the use of OSTEOSET®-T [8]. Prospective
data on OSTEOSET®-T are limited, with published work concentrating on post-traumatic osteomyelitis in long bones but without comparison with controls [9].

Conclusion

This case series supports continued use of OSTEOSET®-T as an adjunct in the treatment of chronic osteomyelitis of the tibia following trauma but highlights potential issues with wound problems. Further prospective and controlled studies are needed to evaluate the role of local antibiotic delivery systems in the treatment of chronic osteomyelitis.

Acknowledgments No financial support was received for this study.

Conflict of interest The authors declare no conflict of interest.

Ethical statement This retrospective human study conforms to the declaration of Helsinki and IRB approval with waiver of informed consent.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Struijs PA, Poolman RW, Bhandari M (2007) Infected nonunion of the long bones. J Orthop Trauma 21(7):507–511
2. Wright Medical Technology Inc (2006) OSTEOSET®-T: medicated bone graft substitute technical monograph. http://www.ossano.com/Produkter/Bensubstitut/Osteoset/651-1097%20R5.06%20OSTEOSET%20T%20Tech%20Monograph.pdf. Accessed 15 Dec 2014
3. Tay BK, Patel VV, Bradford DS (1999) Calcium sulfate- and calcium phosphate-based bone substitutes. Mimicry of the mineral phase of bone. Orthop Clin North Am 30(4):615–623
4. Wahl P, Livio F, Jacobi M, Gautier E, Buclin T (2011) Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material. Arch Orthop Trauma Surg 131:657–662
5. Beardmore AA, Brooks DE, Wenke JC, Thomas DB (2005) Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am 87(1):107–112
6. Thomas BD, Brooks DE, Bice TG, DeJong ES, Lonergan KT, Wenke JC (2005) Tobramycin-impregnated calcium sulfate prevents infection in contaminated wounds. Clin Orthop Relat Res 441:366–371
7. Tsai YH, Tsung-Jen H, Shih HN, Hsu RW (2004) Treatment of infected tibial nonunion with tobramycin-impregnated calcium sulfate: report of two cases. Chang Gung Med J 27(7):542–547
8. Chang W, Colangell M, Colangell S, Di Bella C, Gozzi E, Donati D (2007) Adult osteomyelitis: debridement versus debridement plus Osteoset T® pellets. Acta Orthop Belg 73(2):238–243
9. McKee M, Wild LM, Schemitsch EH, Waddell JP (2002) The use of an antibiotic-impregnated osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial. J Orthopt Trauma 16(9):622–627
10. Wahl P, Livio F, Jacobi M, Gautier E, Buclin T (2011) Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material. Arch Orthop Trauma Surg 131:657–662
11. Wright Medical Technology Inc (2011) OSTEOSET®: resorbable mini-bead kit. http://www.ossano.com/Produkter/Bensubstitut/Osteoset/SK409-511.pdf. Accessed 15 Dec 2014
12. Rang HP, Dale MM, Ritter JM (1999) Rang, Dale and Ritter’s pharmacology, 4th edn. Churchill Livingstone, New York
13. Shakil S, Khan R, Zarrilli R, Khan A (2007) Aminoglycosides versus bacteria—a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci 15(1):5–14
14. Edson RS, Terrell CL (1999) The aminoglycosides. Mayo Clin Proc 74(5):519–528
15. Bennett CL, Weber R (1976) Tobramycin sulfate: a summary of worldwide experience from clinical trials. J Infect Dis 134(Suppl):S219–S234
16. Vuolo J (2004) Current options for managing the problem of excess wound exudate. Prof Nurse 19(9):487–491
17. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE (1998) Role of rifampin for treatment of orthopedic implant-related Staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279:1537–1541
18. Spellberg B, Lipsky B (2012) Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 54(3):393–407